What’s Going On With Oracle Stock Ahead Of Its Q4 Results?
Oracle Corporation's fourth quarter and fiscal year 2024 results will be released on Tuesday, June 11th, after the close of the market.
What’s Going On With Costco Shares Today?
Costco recently reported strong sales growth in May, with comparable sales up and surpassing earnings estimates. Investors can access stock through XLP and FSTA ETFs.
Macron’s Snap Election Gamble Shocks European Markets: Euro Eyes Worst 2-Day Performance In 15 Months
European financial markets tumble after far-right parties gain in European Parliament elections, causing uncertainty and potential challenges.
Cognizant Strengthens Engineering Muscle with $1.3B Belcan Buyout: Details
Cognizant Technology Solutions to acquire Belcan, LLC for $1.3B in cash and stock, expanding its ER&D capabilities and presence in aerospace/defense. Deal expected to close in Sept. 2024, with $800M annual revenue contribution and EPS accretion by 2026.
BP Tightens Workplace Relationship Rules After CEO Firing: Report
BP updates policy, requires employees to disclose intimate relationships or face termination. CEO's dismissal for non-disclosure cited as reason.
Class Action Against Abbott’s Glucerna Products Proceeds in Federal Court
WuXi AppTec employees collaborated with China's PLA on altitude sickness drugs, raising national security concerns in the U.S. Congressional committee calls for restricting biotech ties amid ongoing scrutiny.
Stocks Reclaim Record Highs As Jobs Data Fuels Growth Optimism; Gold, Bonds Tumble As Yields Rise: What’s Driving Markets Friday?
Wall Street returned to reclaim record highs on Friday after a stronger-than-expected jobs report.
IFF’s Focus On Health And Environment Set To Drive Stock Momentum, Says Analyst
Oppenheimer initiates coverage on IFF at Outperform rating with $116 price target. Analyst sees potential for shareholder base shift and ongoing growth. Estimated EPS of $3.94 in FY24, $4.28 in FY25, and $4.61 in FY26. Investors can gain exposure through MVAL and IVEG.
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.
Over 10,000 Lawsuits In Novo Nordisk’s Ozempic Case Assigned to New Judge
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.